Literature DB >> 27751588

Development and Characterization of FLT3-Specific Curcumin-Loaded Polymeric Micelles as a Drug Delivery System for Treating FLT3-Overexpressing Leukemic Cells.

Singkome Tima1, Siriporn Okonogi2, Chadarat Ampasavate2, Chad Pickens3, Cory Berkland4, Songyot Anuchapreeda5.   

Abstract

This study aimed at developing a curcumin (CM) nanoparticle targeted to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 (FLT3) protein on the surface of leukemic cells and at evaluating their properties, specificity, cytotoxicity, and inhibitory effect on FLT3 protein level in FLT3-overexpressing leukemic cells, EoL-1, and MV-4-11 cells. FLT3-specific peptides were conjugated onto modified poloxamer 407 using the copper-catalyzed azide-alkyne cycloaddition reaction. The thin film hydration method was performed for FLT3-specific CM-loaded polymeric micelles (FLT3-CM-micelles) preparation. Flow cytometry and fluorescence microscopy were used to determine rate of cellular uptake. 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay was used to test the cytotoxicity of the micelles on leukemic cells. FLT3-CM-micelles demonstrated a mean particle size less than 50 nm, high entrapment efficiency, and high rate of CM uptake by leukemic cells. The intracellular CM fluorescence is related to FLT3 protein levels on the leukemic cell surfaces. Moreover, FLT3-CM-micelles demonstrated an excellent cytotoxic effect and decreased FLT3 protein expression in the leukemic cells. The FLT3-CM-micelles could enhance both solubility and cytotoxicity of CM on FLT3-overexpressing leukemic cells. These promising nanoparticles may be used for enhancing antileukemic activity of CM and developed as a targeted drug delivery system in the future.
Copyright © 2016 American Pharmacists Association®. All rights reserved.

Entities:  

Keywords:  micelle; nanoparticle; peptides; polymeric drug delivery systems; targeted drug delivery

Mesh:

Substances:

Year:  2016        PMID: 27751588      PMCID: PMC5189693          DOI: 10.1016/j.xphs.2016.09.010

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  57 in total

Review 1.  LFA-1 on leukemic cells as a target for therapy or drug delivery.

Authors:  Rungsinee Phongpradist; Chuda Chittasupho; Siriporn Okonogi; Teruna Siahaan; Songyot Anuchapreeda; Chadarat Ampasavate; Cory Berkland
Journal:  Curr Pharm Des       Date:  2010-07       Impact factor: 3.116

Review 2.  Polymeric micelles as a new drug carrier system and their required considerations for clinical trials.

Authors:  Masayuki Yokoyama
Journal:  Expert Opin Drug Deliv       Date:  2010-02       Impact factor: 6.648

3.  Inhibitory mechanism of pure curcumin on Wilms' tumor 1 (WT1) gene expression through the PKCα signaling pathway in leukemic K562 cells.

Authors:  Suwanna Semsri; Sheryl R Krig; Lakmal Kotelawala; Colleen A Sweeney; Songyot Anuchapreeda
Journal:  FEBS Lett       Date:  2011-06-07       Impact factor: 4.124

Review 4.  Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.

Authors:  Edgar Pérez-Herrero; Alberto Fernández-Medarde
Journal:  Eur J Pharm Biopharm       Date:  2015-03-23       Impact factor: 5.571

Review 5.  Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment.

Authors:  Ornchuma Naksuriya; Siriporn Okonogi; Raymond M Schiffelers; Wim E Hennink
Journal:  Biomaterials       Date:  2014-01-15       Impact factor: 12.479

6.  FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.

Authors:  Rui Zheng; Mark Levis; Obdulio Piloto; Patrick Brown; Brenda R Baldwin; Norbert C Gorin; Miloslav Beran; Zhenping Zhu; Dale Ludwig; Dan Hicklin; Larry Witte; Yiwen Li; Donald Small
Journal:  Blood       Date:  2003-09-11       Impact factor: 22.113

Review 7.  The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.

Authors:  Seth A Wander; Mark J Levis; Amir T Fathi
Journal:  Ther Adv Hematol       Date:  2014-06

8.  Inhibitory effect of turmeric curcuminoids on FLT3 expression and cell cycle arrest in the FLT3-overexpressing EoL-1 leukemic cell line.

Authors:  Singkome Tima; Hideki Ichikawa; Chadarat Ampasavate; Siriporn Okonogi; Songyot Anuchapreeda
Journal:  J Nat Prod       Date:  2014-04-01       Impact factor: 4.050

9.  Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.

Authors:  Jia Rao; Duo-Rong Xu; Fei-Meng Zheng; Zi-Jie Long; Sheng-Shan Huang; Xing Wu; Wei-Hua Zhou; Ren-Wei Huang; Quentin Liu
Journal:  J Transl Med       Date:  2011-05-19       Impact factor: 5.531

Review 10.  Targeted therapy using nanotechnology: focus on cancer.

Authors:  Vanna Sanna; Nicolino Pala; Mario Sechi
Journal:  Int J Nanomedicine       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.